Robert Alexander - 03 Jun 2021 Form 4 Insider Report for Allena Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2021, 16:00:33 UTC
Prior SEC filing: 04 Jun 2021
Next SEC filing: 03 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Kevin Brennan, attorney-in-fact

Key filing fact

Robert Alexander filed Form 4 for Allena Pharmaceuticals, Inc. on 04 Jun 2021.

Key facts

This page summarizes Robert Alexander's Form 4 filing for Allena Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Jun 2021, 16:00.

Change

Previous filing in this sequence was filed on 04 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALNAQ transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +37,000
Change %
Price: $0.000000
Shares after: 37,000
Date: 03 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,000
Exercise price: $1.14
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders.